Research

Hormonal

Tirzepatide stimulates glucagon secretion in human islets primarily through GIP receptor activation, which overrides the glucagon-suppressing effect of GLP-1 receptor activation.

Tirzepatide increases glucagon secretion via the GIP receptor, which might seem counterintuitive for a diabetes drug. However, this is a normal physiological response to nutrient sensing, and the drug's overall effect is still a significant reduction in blood glucose due to its powerful insulin-stimulating effects.

GoodSupportsHIGH confidence
antagonism of the GIPR, but not GLP-1R, completely blocked the ability of either hGIP or tirzepatide to stimulate glucagon secretion.
Kimberley El et al. · Nature Metabolism · 2023

Why this rating

Consistent findings across multiple human donor islet sets.

Source

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

Kimberley El et al. · Nature Metabolism · 2023

DOI 10.1038/s42255-023-00811-0

mechanism_onlyCited 109×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →